Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

New Orleans, Louisiana 70112


Purpose:

The objective of this study is to assess whether prophylactic therapy with an activated prothrombin complex concentrate (FEIBA)will result in a significant reduction in the number of bleeds in patients with hemophilia and persistent high responding inhibitors.


Criteria:

Inclusion Criteria: - hemophilia A, any severity, with documented hisotry of high-titer inhibitor (>5BU); current use of bypassing agents (PCCs, aPCCs or rFVIIa) for treatment of bleeds; >/= 6 bleeds requiring bypassing therapy in the previous 6 months Exclusion Criteria: - concomitant immune tolerance therapy; clinically symptomatic liver disease, platelet count less than 100,000


NCT ID:

NCT00221195


Primary Contact:

Principal Investigator
Cindy A Leissinger
Tulane University School of Medicine

Cindy A Leissinger, MD
Phone: 504-390-2152
Email: cleissi@cox-internet.com


Backup Contact:

N/A


Location Contact:

New Orleans, Louisiana 70112
United States

Cindy Leissinger, MD
Phone: 504-390-2152
Email: cleissi@cox-internet.com

Site Status: Recruiting


Data Source: ClinicalTrials.gov

Date Processed: October 09, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.